Humacyte, Inc. (HUMA)
1.34
-0.05
(-3.60%)
USD |
NASDAQ |
Jun 10, 16:00
1.19
-0.15
(-11.19%)
After-Hours: 20:00
Humacyte Profit Margin (Quarterly) : -3.56K% for March 31, 2026
Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | -3.56K% |
| December 31, 2025 | -5.31K% |
| September 30, 2025 | -2.33K% |
| June 30, 2025 | -12.51K% |
| March 31, 2025 | |
| December 31, 2024 | |
| September 30, 2024 | |
| June 30, 2024 | |
| March 31, 2024 | |
| December 31, 2023 | |
| September 30, 2023 | |
| June 30, 2023 |
| Date | Value |
|---|---|
| March 31, 2023 | |
| December 31, 2022 | |
| September 30, 2022 | -81.55K% |
| June 30, 2022 | |
| March 31, 2022 | -8.51K% |
| December 31, 2021 | |
| September 30, 2021 | -13.10K% |
| June 30, 2021 | -2.49K% |
| March 31, 2021 | -13.10K% |
| December 31, 2020 | |
| September 30, 2020 | -1.94K% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| Altimmune, Inc. | -- |
| Protalix Biotherapeutics, Inc. | 54.27% |
| Agenus, Inc. | -- |
| Amgen, Inc. | 21.02% |
| BioCryst Pharmaceuticals, Inc. | -461.5% |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -974.4% |
| Return on Assets | -78.73% |
| Return on Invested Capital | -122.8% |
| Gross Profit Margin (Quarterly) | -311.7% |
| Operating Margin (Quarterly) | -5.85K% |
| Return on Net Operating Assets | -174.3% |